ELLI, ELENA MARIA
 Distribuzione geografica
Continente #
NA - Nord America 2.096
EU - Europa 1.411
AS - Asia 1.281
SA - Sud America 234
AF - Africa 29
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.057
Nazione #
US - Stati Uniti d'America 2.047
SG - Singapore 514
IT - Italia 419
CN - Cina 317
RU - Federazione Russa 250
DE - Germania 237
BR - Brasile 183
HK - Hong Kong 175
IE - Irlanda 130
SE - Svezia 114
VN - Vietnam 85
GB - Regno Unito 61
IN - India 42
FR - Francia 38
CA - Canada 30
UA - Ucraina 30
FI - Finlandia 29
ID - Indonesia 26
NL - Olanda 24
ES - Italia 21
AR - Argentina 20
TR - Turchia 20
KR - Corea 19
BD - Bangladesh 18
JP - Giappone 18
PL - Polonia 16
MX - Messico 15
ZA - Sudafrica 14
AT - Austria 10
CZ - Repubblica Ceca 10
EC - Ecuador 10
IQ - Iraq 7
PK - Pakistan 7
VE - Venezuela 7
CO - Colombia 5
PY - Paraguay 5
RO - Romania 5
UZ - Uzbekistan 5
ET - Etiopia 4
IR - Iran 4
KE - Kenya 4
SA - Arabia Saudita 4
AU - Australia 3
BG - Bulgaria 3
CL - Cile 3
NO - Norvegia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
BE - Belgio 2
CH - Svizzera 2
GR - Grecia 2
IL - Israele 2
JO - Giordania 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LT - Lituania 2
MA - Marocco 2
PH - Filippine 2
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
FJ - Figi 1
GA - Gabon 1
GE - Georgia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
MM - Myanmar 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.057
Città #
Singapore 315
Ann Arbor 301
Ashburn 256
Hong Kong 172
Frankfurt am Main 146
Milan 129
Dublin 128
Chandler 122
Dallas 95
Woodbridge 90
Fairfield 89
Los Angeles 81
Houston 80
New York 75
Beijing 56
Wilmington 55
Santa Clara 54
Hefei 46
Shanghai 41
Seattle 32
Munich 31
Princeton 30
Cambridge 26
Dearborn 25
Jacksonville 25
Ho Chi Minh City 24
Jakarta 24
São Paulo 23
Altamura 22
Moscow 22
Hanoi 21
Kent 20
Seoul 19
Buffalo 18
Chicago 18
Romola 18
Lawrence 15
Council Bluffs 14
Warsaw 14
Atlanta 13
London 13
Rome 13
Tokyo 13
Denver 12
Orem 12
Poplar 12
The Dalles 12
Turin 12
Turku 12
Chennai 11
Guangzhou 11
Nuremberg 10
Genoa 9
Sesto San Giovanni 9
Dong Ket 8
Helsinki 8
Johannesburg 8
Monza 8
San Jose 8
Brooklyn 7
Carate Brianza 7
Desio 7
Olomouc 7
Querétaro 7
Salt Lake City 7
San Francisco 7
Andover 6
Changsha 6
Cinisello Balsamo 6
Como 6
Fremont 6
Mexico City 6
Montreal 6
Ottawa 6
Pune 6
Rio de Janeiro 6
Stockholm 6
Toronto 6
Dhaka 5
Falls Church 5
Lappeenranta 5
Meda 5
Miami 5
Mumbai 5
Nanjing 5
New Delhi 5
St Petersburg 5
Tashkent 5
Ankara 4
Assago 4
Baghdad 4
Biên Hòa 4
Boardman 4
Bologna 4
Brasília 4
Cape Town 4
Caxias do Sul 4
Charlotte 4
City of London 4
Columbus 4
Totale 3.205
Nome #
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 313
Large-Scale Analysis of SARS-CoV-2 Synonymous Mutations Reveals the Adaptation to the Human Codon Usage During the Virus Evolution 310
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 309
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 309
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 306
Idiopathic erythrocytosis: a germline disease? 275
Integrated Genomic, Functional and Prognostic Characterization of Atypical Chronic Myeloid Leukemia (aCML) in a Cohort of 43 Patients 269
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 248
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 236
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia 223
Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study 219
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors 216
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis 209
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 203
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 200
Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study 194
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review 184
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 182
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 152
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis 148
First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis Mimicking Triple Negative Myelofibrosis 147
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 146
JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib 142
Totale 5.140
Categoria #
all - tutte 17.724
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.724


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021214 0 0 0 0 0 40 26 34 30 23 40 21
2021/2022217 17 12 18 21 16 19 1 11 16 19 27 40
2022/2023527 45 148 65 50 25 78 11 27 38 5 10 25
2023/2024569 16 25 24 35 58 132 96 22 50 28 25 58
2024/20251.335 60 99 79 78 109 65 71 50 148 244 128 204
2025/20261.671 398 149 254 417 347 106 0 0 0 0 0 0
Totale 5.140